Reply  by Attie, Fause
LETTERS TO THE EDITOR
Surgery for Atrial Septal Defect
Attie et al. (1) are to be congratulated for their ambitious
randomized study of surgery for secundum atrial septal defect
(ASD) in patients over age 40. I believe, however, that their results
do not support their recommendation for surgery in this patient
group.
The only end point that was significantly less frequent in the
surgical group than in the medical group was recurrent pneumonia.
This single component of the composite end point accounted for
three-quarters of the difference between the two groups. There was
no difference between the two groups with respect to heart failure,
pulmonary embolism, peripheral embolism, stroke or total mor-
tality (the authors’ attempt to demonstrate a difference in mortality
by means of complex statistical manipulation notwithstanding).
According to the study, the net gain from the performance of 232
operations for the correction of ASD in patients over age 40 would
be the prevention of approximately 18 cases of pneumonia. In my
opinion such a benefit is hardly worth the cost and suffering the
surgery would cause.
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REPLY
We thank Dr. Bassan very much for his interest about our recent
article concerning surgery for atrial septal defect (ASD) in adults
(1). Our explanation follows.
A compound index is a common strategy recently used for
developing some clinical trials in which the sample size for a
specific “end point” is either not possible or very difficult to obtain
(2). When the sample size is calculated for a compound index, and
it is defined as the primary “end point,” the analysis at the
conclusion of the study should be directed to this “end point” as a
“package” (2,3). Of course, the curiosity to see what happened in
the compound index is unavoidable, but caution needs to be
considered in the interpretation of the results. The way that Dr.
Bassan analyzed the data, we can see that sudden death was almost
significant, but the small number of cases probably did not permit
this conclusion. The high incidence of pneumonia was certainly
unexpected. We do not have a clear explanation for this feature;
however, pulmonary infection was responsible for 28.7% of the
total mortality. Recurrent pneumonia is a difficult diagnosis to be
easily differentiated from pulmonary infarct in these types of
patients. We believe that the pulmonary infarct was probably
underestimated. Our study is the first randomized clinical trial
published about this specific topic, and no complex statistical
manipulation was done (4,5), because the data are the data!
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Toward a Redefinition of Ischemic
Cardiomyopathy: Is It an Indivisible Entity?
We read with great interest the article by Felker et al. (1) in which
the investigators raised an important question regarding definitions
of ischemic cardiomyopathy (CMP). Based on prognostic differ-
ences, the researchers proposed a new definition of ischemic
cardiomyopathy that reclassifies cases with single-vessel disease as
nonischemic patients.
However, the magnitude of this problem seems considerably
deeper. Conventionally, the pathogenesis of ischemic CMP is
described as sequelae of single or recurrent myocardial infarctions
(MIs), with loss of functioning myocytes, development of fibrosis
and subsequent left ventricular (LV) dysfunction and remodeling.
In contrast, in 1989 Atkinson and Virmani (2) described conges-
tive heart failure due to severe coronary artery disease (CAD)
without MI in 26% of consecutive necropsies with ischemic CMP.
Its pathogenesis in absence of MI was unclear at that time. They
presumed that although this type of coronary CMP may comprise
a subset of ischemic CMP, it may also represent idiopathic-dilated
CMP with coincidental CAD.
Recent investigations have elucidated the pathogenesis of isch-
emic CMP in absence of MI, suggesting that LV function
impairment is related to progression of CAD and does not require
a distinct coronary event, such as MI with enzymatic elevation (3).
Hibernation subsequent to severe CAD represents a precarious
balance between perfusion and tissue viability that cannot be
maintained indefinitely; small but multiple foci of myocardial
necrosis will ultimately occur if blood flow is not increased (4). At
onset of heart failure, myocyte apoptosis occurs (5) contributing to
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